Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $22.6MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| George Jeffrey P. | Director | Mar 27 '26 | Buy | $8.92 | 5,592 | $49,890 | 5,592 | Mar 30 08:47 AM |
| Schimmelpennink Evert B. | President, CEO and Secretary | Mar 27 '26 | Buy | $8.95 | 28,089 | $251,411 | 77,289 | Mar 30 08:46 AM |
| Chevallard Daniel R. | Chief Financial Officer | Mar 27 '26 | Buy | $8.57 | 7,500 | $64,275 | 12,886 | Mar 30 08:46 AM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.